Maja P. Navodnik, MD, is head of the Sub-Department for Diabetes and Endocrinology (part of the Department of Angiology, Endocrinology, and Rheumatology at the General Hospital Celje, Slovenia. She graduated from the Faculty of Medicine at the University of Ljubljana in 1996. She obtained her specialty in internal medicine from the University Medical Centre Ljubljana, Slovenia in 2003. She was certified in diabetes, endocrinology, and angiology at the University Medical Center Ljubljana, in the clinical department for diabetes in endocrinology and angiology, as well as the clinical department for radiology, Clinical Hospital Dubrava Zagreb Croatia. She also completed a postgraduate course in advanced technology for DM. She is a board member of the Slovenian Diabetes Association and a member of the Slovenian Endocrinologic Association and Slovenian Association for Vascular Diseases. She has been a board member for many pharmaceutical companies (Lilly, AstraZeneca, Boehringer, Amgen, and Novo Nordisk). Her first international GCP course was completed in 2005, after which she participated in many international trials as the site principal investigator or sub-investigator in Phase II, III, and IV trials (TREAT, RELYPSA, SWITCH, AWARD 8, DUAL IX, SUSTAIN 10, and PIONEER PLUS). She has spoken at numerous national professional meetings, as well as participated in various poster and oral sessions at international meetings.
Maja P. Navodnik, MD, is head of the Sub-Department for Diabetes and Endocrinology (part of the Department of Angiology, Endocrinology, and Rheumatology at the General Hospital Celje, Slovenia. She graduated from the Faculty of Medicine at the University of Ljubljana in 1996. She obtained her specialty in internal medicine from the University Medical Centre Ljubljana, Slovenia in 2003. She was certified in diabetes, endocrinology, and angiology at the University Medical Center Ljubljana, in the clinical department for diabetes in endocrinology and angiology, as well as the clinical department for radiology, Clinical Hospital Dubrava Zagreb Croatia. She also completed a postgraduate course in advanced technology for DM. She is a board member of the Slovenian Diabetes Association and a member of the Slovenian Endocrinologic Association and Slovenian Association for Vascular Diseases. She has been a board member for many pharmaceutical companies (Lilly, AstraZeneca, Boehringer, Amgen, and Novo Nordisk). Her first international GCP course was completed in 2005, after which she participated in many international trials as the site principal investigator or sub-investigator in Phase II, III, and IV trials (TREAT, RELYPSA, SWITCH, AWARD 8, DUAL IX, SUSTAIN 10, and PIONEER PLUS). She has spoken at numerous national professional meetings, as well as participated in various poster and oral sessions at international meetings.